KATASTROFİK ANTİFOSFOLİPİD SENDROM 

Tanım: Antifosfolipid antikorsendromu klinik olarak bir veya daha fazla venöz ve/veya arteryel tromboz atağı ve/veya obstetrik komplikasyonlar, laboratuar olarak antifosfolipid ve antikardiyolipin antikorlar ve/veya anti-beta2 glikoprotein 1 pozitifliği ile karakterize bir hiperkoagülabilite sendromudur. Katastrofik antifosfolipid sendromu ise antifosfolipid antikorları olan hastalarda en az 3 organ sisteminde günler, haftalar içerisinde oluşan akut başlangıçlı trombozlar ile karakterize bir klinik tablodur. 

Gerekçe: Katastrofik antifosfolipid sendromunda terapötik aferezin tam etki mekanizması bilinmemektedir. Ancak; patolojik antifosfolipid antikorların sitokinler, tümör nekrozis faktör alfa ve kompleman gibi ortamdan uzaklaştırılmasının önemli bir rol oynadığı düşünülmektedir. 

İşlem: TPD, DFPP, CF 

İşlenen Volüm: 1-1.5 TPH 

Sıklığı: Günlük 

Replasman Sıvısı: TDP, albumin. 

Uygulama sayı ve/veya süresi: Çoğu hastada 3-5 işlem yapılmaktadır. Tedavi süresini belirleme ve kesmede kullanılan herhangi bir klinik ve laboratuvar ölçütü bulunmamaktadır. 

YARARLANILAN LİTERATÜRLER

*Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508–512. 

*Asherson RA. The catastrophic antiphospholipid (Asherson‘s) syndrome in 2004—a review. Autoimmun Rev 2005;4:48–54. 

*Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530– 534. 

*Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, Lim K, Munoz-Rodriguez FJ, Levy RA, Boue F, Rossert J, 

*Ingelmo M. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195–207. 

*Cervera R, Font J, Gomez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, Ramos-Casals M, Ingelmo M, Piette JC, Shoenfeld Y, Asherson RA. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005;64:1205–1209. 

Triplett DA, Asherson RA. Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Hematol 2000;65:154–159. 

*Flamholz R, Tran T, Grad GI, Mauer AM, Olopade OI, Ellman MH, McKinsey JF, Jeon HR, Baron JM, Baron BW. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta-glycoprotein I antibodies as a marker of response to therapy. J Clin Apher 1999;14:171–176.

*Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, Lim E, Lau TC, Gurjal A, Jedryka-Goral A, Chwalinska-Sadowska H, Dibner RJ, Rojas-Rodriguez J, Garcia-Carrasco M, Grandone JT, Parke AL, Barbosa P, Vasconcelos C, Ramos-Casals M, Font J, Ingelmo M. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine 2001;80:355–377. 

*Uthman I, Shamseddine A, Taher A. The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome. Transfus Apher Sci 2005;33:11–17. 

*Vora SK, Asherson RA, Erkan D. Catastrophic antiphospholipid syndrome. J Intensive Care Med 2006;21:144–159. 

*Shah AA, Higgins JP, Chakravarty EF. Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties. Nat Clin Pract Rheumatol 2007;3:357–362. 

Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome:pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008;34:290–294. 

*Cervera R, Bucciarelli S, Plasin MA, Gomez-Puerta JA, Plaza J, Pons-Estel G, Shoenfeld Y, Ingelmo M, Espinos G. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the ‗‗CAPS Registry‘‘. J Autoimmun 2009;32:240–245. 

*Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 2009;5:160–170.